Amgen cancer drug Kyprolis to get expedited review from FDA
An experimental multiple myeloma treatment using Amgen’s Kyprolis will get an expedited review from the U.S. Food and Drug Administration. The FDA said it will use an expedited review process to review a multiple-myeloma treatment using Kyprolis and the genric drug dexamethasone. On July 23, Amgen submitted additional data to the FDA which compared this Read More →
Limoneira, Lewis Group partner to build 1,500 homes in Santa Paula
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Hewlett-Packard laying off 25,000 to 30,000 employees
Hewlett-Packard is laying off 25,000 to 30,000 employees globally as part of a restructuring program that will save the company $2.7 billion per year. HP announced the layoffs on Sept. 15 at a meeting of its securities analysts. The cuts represent about 10 percent of HP’s workforce of about 302,000. It wasn’t immediately clear how Read More →
Amgen licenses cancer drug to NatPharma
Amgen has licensed an experimental cancer drug to a Chicago biotech company founded and controlled by billionaire Patrick Soon-Shiong. NatPharma LLC is licensing the rights to AMG 337 from Thousand Oaks-based Amgen to develop and sell AMG 337. The drug is an experimental, phase-two cancer treatment. The licensing agreement is the second between Amgen and Read More →
Goleta-based Deckers hits 52-week low for stock price
Goleta-based Deckers Brands hit a 52-week low on Sept. 11 when it briefly fell to $59.62 per share. It closed Sept. 14 at $61.10. Shares of Deckers dropped about 33 percent so far this year from $89.74 on Jan. 2 before it closed at $60.65 on Sept. 11. Investment research firm Zacks said weak earnings Read More →
